{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.918","value":"-13.11"},{"groupId":"OG001","spread":"9.517","value":"-16.85"},{"groupId":"OG002","spread":"9.202","value":"-18.17"},{"groupId":"OG003","spread":"8.293","value":"-18.02"},{"groupId":"OG004","spread":"13.113","value":"-4.54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"49"}],"units":"Participants"}],"description":"The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, patient and physician global assessment of disease activity and CRP. The equation used to calculate the SDAI:SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10, with lower values indicating fewer symptoms.","dispersionType":"Standard Deviation","groups":[{"description":"Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG000","title":"1 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG001","title":"2 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG002","title":"4 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG003","title":"8 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.","id":"OG004","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All participants who received any amount of study drug in Part A and had SDAI data at analysis time points. The last non-missing post-baseline value in Part A was used.","reportingStatus":"POSTED","timeFrame":"Baseline up to 12 weeks","title":"Mean Change in Simplified Disease Activity Index (SDAI) Responses up to 12 Weeks (Part A)","type":"SECONDARY","unitOfMeasure":"units on a scale"}